Spondyloarthritis & psoriatic arthritis
Sámi psoriatic arthritis patients in northern Norway receive less conventional synthetic disease-modifying anti-rheumatic drug treatment and have more arthritis, axial symptoms, and joint damage
Authors' conclusion
Sámi PsA patients show higher rates of axial involvement, arthritis, and joint damage than their non-Sámi peers. Furthermore, Sámi patients demonstrate underutilization of csDMARDs.
Study context
- Population
- Adult PsA patients meeting ClASsification for Psoriatic ARthritis (CASPAR) criteria, Norwegian Arthritis Registry and hospitals in northern Norway
- Participants
- 424 patients
- Exposure
- Sámi vs non-Sámi PsA patients
- Outcome
- Differences in treatment and joint damage
Methodological detailsregistry- and hospital-based, binary logistic regression adjusted for age and gender
- Registry- and hospital-based
- Binary logistic regression adjusted for age and gender
Main finding
As reported in the abstract
Joint damage
P = 0.010
- Highest rate among Sámi men
- P = 0.005
Observational data: associations, not effects.
Further findings
Arthritis prevalence
P = 0.007
Axial involvement
P = 0.033
- csDMARD use (men subgroup) — Sámi men vs non-Sámi men: csDMARD use · significant underutilization in Sámi men
- 83% vs 92% · P = 0.031
- MTX use (men subgroup) — Sámi men vs non-Sámi men: MTX use
- 68% vs 90% · P = 0.002
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Sámi psoriatic arthritis patients in northern Norway receive less conventional synthetic disease-modifying anti-rheumatic drug treatment and have more arthritis, axial symptoms, and joint damage. Scand J Rheumatol. Published 3 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →